WST:NYE-West Pharmaceutical Services Inc.

EQUITY | Medical Instruments & Equipment | New York Stock Exchange

Last Closing

USD 105.25

Change

0.00 (0.00)%

Market Cap

USD 5.90B

Volume

0.48M

Analyst Target

USD 112.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

West Pharmaceutical Services Inc develops, manufactures and sells packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, and prefillable syringe components.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-20 )

Largest Industry Peers for Medical Instruments & Equipment

ETFs Containing WST

SANE 6.08 % 0.00 %

N/A

N/A
HLTH:AU VanEck Global Healthcare .. 2.21 % 0.00 %

N/A

USD 0.06B
RSPH Invesco S&P 500® Equal.. 1.71 % 0.00 %

-0.22 (-0.74%)

USD 1.02B
EQWM 0.00 % 0.25 %

N/A

N/A
MIDZ 0.00 % 0.97 %

N/A

N/A
MYY ProShares Short MidCap400 0.00 % 0.95 %

+0.19 (+-0.74%)

USD 6.08M
MZZ ProShares UltraShort MidC.. 0.00 % 0.95 %

+0.19 (+-0.74%)

USD 1.59M
NOBL 0.00 % 0.35 %

N/A

N/A
PXMG 0.00 % 0.39 %

N/A

N/A
PEXL Pacer US Export Leaders E.. 0.00 % 0.60 %

-0.64 (-0.74%)

USD 0.06B
PQLC 0.00 % 0.00 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.05B
CB5:LSE Amundi ETF MSCI Europe Ba.. 0.00 % 0.00 %

+137.50 (+-0.74%)

USD 0.04B
SMDD ProShares UltraPro Short .. 0.00 % 0.95 %

+0.30 (+-0.74%)

USD 3.21M
BMED BlackRock Future Health E.. 0.00 % 0.00 %

-0.14 (-0.74%)

USD 4.14M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Equipment) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.37% 71% C- 56% F
Dividend Return N/A N/A N/A N/A F
Total Return 7.37% 71% C- 55% F
Trailing 12 Months  
Capital Gain 4.61% 46% F 86% B+
Dividend Return 0.43% 30% F 5% F
Total Return 5.04% 38% F 82% B
Trailing 5 Years  
Capital Gain 109.54% 40% F 94% A
Dividend Return 4.68% 22% F 15% F
Total Return 114.21% 40% F 94% A
Average Annual (5 Year Horizon)  
Capital Gain 22.79% 69% C- 93% A
Dividend Return 23.56% 62% D 93% A
Total Return 0.78% 27% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 13.78% 85% B 53% F
Risk Adjusted Return 170.94% 85% B 98% N/A
Market Capitalization 5.90B 46% F 84% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Equipment) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.40 54% 10%
Price/Book Ratio 6.08 38% 10%
Price / Cash Flow Ratio 6.70 38% 14%
Price/Free Cash Flow Ratio 40.33 38% 11%
Management Effectiveness  
Return on Equity 11.87% 69% 63%
Return on Invested Capital 32.38% 92% 93%
Return on Assets 8.20% 85% 83%
Debt to Equity Ratio 15.00% 92% 86%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.